公开(公告)号：US20190307731A1

公开(公告)日：2019-10-10

申请号：US16229408

申请日：2018-12-21

申请人： Ariagen, Inc.

发明人： Luqing YANG ,  Guodong LI ,  Suoming ZHANG

IPC分类号： A61K31/4245 ,  A61K31/433 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/404 ,  A61K31/437 ,  A61K31/7056 ,  A61K31/497 ,  A61K31/5377 ,  A61P35/04

摘要： Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R′ is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra are independently H or two Ra together form ═O or ═N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, O, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C═N and interrupted by 1 to 3 heteroatoms selected from N, O, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, O, and S; and R is Rc which is C-attached or RN which is N-attached. The compounds of formula (I) of the present invention can regulate AhR activity, and can be used to inhibit the growth of cancer cells and inhibit the metastasis and invasion of tumor cells.